Zepbound is a popular weight-loss drug manufactured by Eli Lilly. The pharmaceutical company is facing increasing competition from compounding pharmacies and other industry players like Novo Nordisk. To maintain market share, Eli Lilly is strategically adjusting its pricing and distribution methods. - Eli Lilly is offering higher doses of Zepbound in vials at a reduced price compared to the autoinjector pens. - The price reduction is approximately $150 less than the cost of the injector pen version. - This strategic move aims to increase demand for Zepbound and attract more cash-paying customers. - The lower prices are available through LillyDirect, the company's direct-to-consumer website. - The price cut is also intended to compete with cheaper, copycat versions of the drug and rival Novo Nordisk.